ISSN: 2320-7159
IJMR
INTERNATIONAL JOURNAL OF MEDICAL RESEARCH

NARRATIVE REVIEW

A Dual Burden Dilemma: Navigating the Global Impact of Communicable and Non-Communicable Diseases and the Way Forward

Nisarg Goswami[1]

Dr. Nisarg Goswami (Email: nisargsgoswami@gmail.com)

DOI: https://doi.org/10.55489/ijmr.11202412

Citation: Goswami N. A Dual Burden Dilemma: Navigating the Global Impact of Communicable and Non-Communicable Diseases and the way forward. Intl J Med Res 2024;12(3):65-77. DOI: 10.55489/ijmr.11202412

Received: May 15, 2024
Accepted: June 20, 2024
Published: July 01, 2024

Funding: Non-Declared.

Conflict of interests: The authors have declared that no conflict of interests exists.

Publisher: Medsci Publications, India

ABSTRACT

The global burden of disease has shifted significantly, with communicable diseases (CDs) like HIV/AIDS, tuberculosis, and malaria increasingly intersecting with the rising prevalence of non-communicable diseases (NCDs) such as cardiovascular diseases, cancers, and diabetes. This narrative review explores the dual burden posed by CDs and NCDs, emphasizing their interconnections, societal impacts, and regional disparities. While CDs continue to challenge healthcare systems in low- and middle-income countries, NCDs dominate global mortality, driven by aging populations, urbanization, and lifestyle changes. The review highlights how infectious agents contribute to chronic diseases, such as hepatitis B leading to liver cancer or COVID-19 exacerbating diabetes and cardiovascular risks. It underscores the necessity for integrated healthcare approaches that address both disease categories to reduce health inequities. Regional and demographic disparities, such as higher disease burdens in sub-Saharan Africa and Southeast Asia, are also discussed, along with their socioeconomic drivers. Global efforts, including vaccination programs, lifestyle interventions, and sustainable health policies, are evaluated for their effectiveness and challenges. The review concludes with a call for innovative, equity-focused strategies to mitigate the dual burden and strengthen global health resilience.

Keywords: Dilemma, CDs and NCDs, Global Impact, Communicable Diseases, Non-Communicable Diseases

INTRODUCTION

The global burden of disease (GBD) refers to the impact of health problems on populations worldwide, measured by metrics such as mortality, morbidity, disability, and economic cost. It provides a comprehensive framework for understanding how diseases, injuries, and risk factors affect human health over time. In recent decades, substantial progress has been made in reducing the burden of many communicable diseases (CDs), such as HIV/AIDS, malaria, and tuberculosis, through advancements in prevention, diagnosis, and treatment. However, the rise of non-communicable diseases (NCDs), such as cardiovascular diseases, cancer, diabetes, and chronic respiratory conditions, has shifted the global health landscape dramatically. Currently, NCDs account for approximately 74% of global deaths, with developing regions increasingly shouldering a double burden of CDs and NCDs.[1][2]

Analysing communicable and non-communicable diseases together is critical for multiple reasons. First, these diseases are often interconnected. For example, chronic infections like hepatitis B and human papillomavirus (HPV) are major contributors to liver and cervical cancers, respectively.[3][4] Similarly, the aftermath of communicable diseases such as COVID-19 has been linked to increased cardiovascular and metabolic complications, highlighting the complex interplay between CDs and NCDs.[5] Second, addressing the dual burden is essential for developing integrated health policies, especially in low- and middle-income countries (LMICs), where resources are constrained, and healthcare systems often struggle to cope with competing priorities.[6][7]

This narrative review aims to provide an overview of the global burden of communicable and non-communicable diseases, emphasizing their prevalence, incidence, and societal impact. It seeks to explore how the distribution of disease burden varies across regions and populations, particularly in the context of socioeconomic disparities. Additionally, the review will highlight key trends, challenges, and interventions aimed at mitigating the burden of diseases globally. By synthesizing current knowledge, this review aspires to identify gaps in research and policy that warrant further attention to improve global health outcomes and equity.

COMMUNICABLE DISEASES: A PERSISTENT CHALLENGE

Communicable diseases (CDs) continue to pose significant challenges to global health, particularly in low- and middle-income countries (LMICs) where healthcare systems are often overburdened. These diseases are caused by infectious agents such as bacteria, viruses, fungi, and parasites and are typically transmitted through direct or indirect contact. Despite considerable advancements in public health, communicable diseases remain among the leading causes of morbidity and mortality globally.[1][8]

Overview of Major Communicable Diseases

Since its discovery in the 1980s, HIV/AIDS has claimed over 40 million lives. While antiretroviral therapy (ART) has significantly reduced mortality and improved quality of life, approximately 39 million people were living with HIV by the end of 2022, with sub-Saharan Africa bearing the greatest burden.[9][10]

Tuberculosis is the second leading infectious cause of death worldwide after COVID-19, with an estimated 10.6 million new cases and 1.6 million deaths reported in 2021. The disease is exacerbated by factors such as poverty, malnutrition, and co-infections with HIV.[11][12]

Despite ongoing eradication efforts, malaria caused approximately 619,000 deaths in 2021, with children under five accounting for 77% of fatalities. Sub-Saharan Africa remains the epicenter of the disease, driven by Anopheles mosquito vectors and challenges in healthcare access.[13][14]

Emerging Diseases like the COVID-19 pandemic underscored the global vulnerability to emerging infectious diseases, causing over 6.9 million deaths as of 2023. Beyond its direct health impact, COVID-19 disrupted economies, strained healthcare systems, and exacerbated health inequities.[15][16]

The incidence and prevalence of CDs exhibit significant regional variation. For instance,

sub-Saharan Africa accounts for over two-thirds of global HIV cases, while Southeast Asia reports the highest TB burden.[9][12] Similarly, malaria is heavily concentrated in tropical regions, particularly Africa and parts of Asia.[14] The prevalence of CDs in LMICs is often driven by socio-economic factors such as poverty, inadequate sanitation, and limited access to healthcare.[7]

Social, Economic, and Healthcare System Impacts

Communicable diseases have profound social and economic consequences. They disproportionately affect vulnerable populations, perpetuating cycles of poverty and inequality. For example: Malaria alone is estimated to cost Africa over $12 billion annually in lost productivity.[17] COVID-19 overwhelmed hospitals, disrupted routine immunization programs, and diverted resources from other critical health interventions.[15][18] Diseases such as HIV/AIDS and TB often lead to stigma, further marginalizing affected individuals.[12][19]

Advances in Prevention and Control

Remarkable progress has been made in combating CDs through preventive and therapeutic strategies. Immunization campaigns against diseases like measles, polio, and COVID-19 have saved millions of lives globally.[20][21] Interventions such as insecticide-treated bed nets and indoor spraying have significantly reduced malaria transmission.[14][22] Programs such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and the World Health Organization's (WHO) "End TB Strategy" have galvanized resources and policy attention.[12][23]

Despite these advancements, challenges such as antimicrobial resistance, vaccine hesitancy, and inequitable access to healthcare persist. Addressing these barriers will require sustained international collaboration and investment.

NON-COMMUNICABLE DISEASES: A GROWING EPIDEMIC

Non-communicable diseases (NCDs) represent one of the most significant global health challenges of the 21st century. Unlike communicable diseases, NCDs are not caused by infectious agents but arise from a complex interplay of genetic, behavioral, environmental, and metabolic factors. Collectively, NCDs account for 74% of global deaths annually, with low- and middle-income countries (LMICs) disproportionately bearing the brunt of the burden.[24][25] As urbanization accelerates, populations age, and lifestyles shift, the prevalence of NCDs continues to rise, threatening global health systems and economies.[26][27]

Overview of Leading Non-Communicable Diseases

CVDs are the leading cause of death globally, responsible for 17.9 million deaths annually, equating to 32% of all global deaths.[28] Conditions such as ischemic heart disease and stroke dominate this category, driven by hypertension, obesity, and sedentary lifestyles.

Cancer accounts for nearly 10 million deaths annually, with lung, breast, colorectal, prostate, and stomach cancers being the most prevalent.[29] Tobacco use, alcohol consumption, and environmental pollutants are key contributors. Low-resource settings face additional challenges due to late-stage diagnoses and inadequate access to care.[30]

An estimated 537 million adults worldwide were living with diabetes in 2021, a number projected to rise to 643 million by 2030.[31] Type 2 diabetes, linked to obesity and unhealthy diets, constitutes the majority of cases. Its complications, such as kidney failure and lower-limb amputations, significantly impair quality of life.

CRDs, including chronic obstructive pulmonary disease (COPD) and asthma, affect over 500 million people globally.[32] Risk factors include tobacco smoke, air pollution, and occupational exposures.

The prevalence of NCDs has been driven by several interrelated factors. Rapid urban growth has increased exposure to sedentary lifestyles, unhealthy diets, and environmental pollution.[33][34] With life expectancy rising, older populations are more susceptible to chronic diseases like cancer and CVD.[35] Smoking, alcohol use, physical inactivity,

and diets high in sugar and fats significantly contribute to the global NCD burden.[36]

Economic Burden and Long-Term Healthcare Needs

NCDs exert a profound economic toll on individuals and societies. The management of chronic conditions, including frequent hospitalizations, long-term medications, and rehabilitation, imposes heavy financial burdens.[37][38] Premature deaths and disability reduce workforce participation, costing economies trillions annually.[39] For instance, between 2011 and 2025, NCDs are projected to cost LMICs $7 trillion.[40]

Progress in Prevention and Management

Efforts to combat NCDs have focused on prevention, early detection, and management. Public health initiatives, such as anti-tobacco campaigns and dietary guidelines, have raised awareness about risk factors.[41][42] Programs promoting physical activity, healthy eating, and smoking cessation have shown significant success in reducing NCD risk.[43][44] Global frameworks like the WHO Global Action Plan for the Prevention and Control of NCDs 2013–2030 emphasize reducing key risk factors through multi-sectoral approaches.[45]

Despite progress, achieving equity in NCD prevention and care remains a challenge. Strengthening healthcare systems, addressing socio-economic determinants, and fostering global cooperation are critical to reversing the rising tide of NCDs.

INTERACTION BETWEEN COMMUNICABLE AND NON-COMMUNICABLE DISEASES

The interplay between communicable diseases (CDs) and non-communicable diseases (NCDs) represents a critical yet often underappreciated aspect of global health. Certain infectious agents play a significant role in the development of NCDs, creating a continuum of disease that exacerbates the health burden on individuals and healthcare systems. This interrelationship, commonly referred to as the "dual disease burden," highlights the necessity for integrated approaches to disease prevention and management.[1][12]

How Infections Contribute to NCDs

Infectious agents are directly linked to the development of several chronic diseases through persistent inflammation, cellular damage, and disruption of normal physiological processes. Chronic infection with hepatitis B (HBV) or hepatitis C virus (HCV) significantly increases the risk of hepatocellular carcinoma, the most common form of liver cancer. Globally, HBV and HCV are responsible for approximately 80% of liver cancer cases.[46][47]

HPV infection is the primary cause of cervical cancer, accounting for nearly all cases globally. Vaccination against HPV has proven highly effective in reducing the incidence of this cancer, particularly in high-burden regions.[48][49]

Infection with H. pylori, a common bacterial pathogen, is a major risk factor for gastric cancer. It induces chronic inflammation and, in some cases, leads to malignant transformations.[50]

Individuals living with HIV are at increased risk for cardiovascular diseases, certain cancers (e.g., Kaposi's sarcoma), and chronic kidney disease, often due to long-term immune activation and antiretroviral therapy side effects.[51][52]

Impact of Dual Disease Burden on Healthcare Systems and Populations

The coexistence of CDs and NCDs compounds the strain on healthcare systems, particularly in low- and middle-income countries (LMICs). Managing the dual burden requires significant resources for diagnostic, preventive, and therapeutic services. For example, co-management of HIV and associated NCDs like cardiovascular diseases demands integrated care models, which are often lacking in resource-limited settings.[53][54] The dual burden increases healthcare expenditure and reduces productivity due to prolonged illness, disability, or premature death. For instance, chronic liver disease caused by hepatitis infections imposes long-term costs on individuals and governments alike.[39][55] Patients dealing with both CDs and NCDs may face stigma, isolation, and reduced access to essential care, further exacerbating health inequities.[56]

Case Examples Illustrating Overlaps

HIV and Cardiovascular Disease: Research indicates that individuals with HIV are at 1.5 to 2 times higher risk for developing cardiovascular diseases compared to the general population. Factors include chronic inflammation due to the infection, as well as metabolic side effects of antiretroviral therapy.[52][57]

HPV and Cervical Cancer in LMICs: In sub-Saharan Africa, high prevalence rates of HPV combined with inadequate access to screening and vaccination have resulted in disproportionately high cervical cancer rates. Integrated programs offering HPV vaccination alongside other health services have shown promise in mitigating this burden.[49][58]

COVID-19 and Diabetes: The COVID-19 pandemic has underscored the bidirectional relationship between CDs and NCDs. People with diabetes were found to be at higher risk for severe COVID-19 outcomes, while emerging evidence suggests that COVID-19 may trigger new-onset diabetes or worsen existing cases.[59][60]

Addressing the intersection between CDs and NCDs requires holistic public health strategies that integrate prevention, screening, and treatment efforts across both disease categories. This includes fostering multi-sectoral collaboration, scaling up vaccination programs, and strengthening health systems to provide coordinated care.

REGIONAL AND DEMOGRAPHIC DISPARITIES

The burden of diseases, both communicable and non-communicable, is unevenly distributed across regions, income levels, and demographic groups. These disparities are shaped by socio-economic, cultural, environmental, and healthcare access factors, creating profound inequities in health outcomes globally. Vulnerable populations, such as children, the elderly, and socioeconomically disadvantaged groups, face a disproportionate burden of disease, necessitating targeted interventions and equitable health policies.[1][61]

Variations in Disease Burden by Income Levels and Geographic Regions

Low- and Middle-Income Countries (LMICs) bear a higher burden of CDs such as malaria, tuberculosis, and HIV/AIDS. For example, 94% of global malaria cases and deaths occur in Africa, driven by limited access to prevention and treatment.[62][63] While NCDs are traditionally associated with high-income countries (HICs), LMICs are experiencing a rapid rise due to urbanization and lifestyle changes. By 2030, LMICs are projected to account for over 80% of global NCD-related deaths.[39][64]

The African region faces a dual burden, with high rates of CDs like HIV/AIDS and a growing prevalence of NCDs such as diabetes and hypertension.[65] Southeast Asia has high rates of tuberculosis and cardiovascular diseases, reflecting both endemic CDs and the impact of urbanization and industrialization.[66][67] In Western Europe and North America CDs are largely under control, NCDs like obesity, diabetes, and cancer dominate the disease burden.[68]

Vulnerable Populations

CDs such as pneumonia, diarrhea, and malaria remain leading causes of death among children under five in LMICs. In 2021 alone, over 5 million children under five died, with a significant proportion due to preventable and treatable diseases.[69][70] Childhood obesity and early-onset diabetes are rising in both HICs and LMICs, driven by unhealthy diets and sedentary lifestyles.[71][72]

Older adults are at heightened risk for NCDs like cardiovascular diseases, cancers, and Alzheimer's disease. Aging populations, particularly in regions like Europe and East Asia, amplify healthcare demands.[73][74] The elderly are also more vulnerable to severe outcomes from CDs like influenza and COVID-19, highlighting the need for targeted vaccination campaigns.[75][76]

Poverty exacerbates exposure to risk factors, limits access to healthcare, and increases vulnerability to both CDs and NCDs. For example, slum dwellers in urban areas face higher rates of tuberculosis and respiratory diseases due to overcrowding and poor air quality.[12][77]

Indigenous populations often experience disproportionately high rates of both CDs and NCDs due to historical marginalization, limited healthcare access, and socio-cultural barriers.[78][79]

Impact of Cultural, Environmental, and Economic Factors

Dietary practices, traditional medicine, and health-seeking behaviors vary significantly across regions. For instance, cultural stigma around HIV/AIDS can hinder diagnosis and treatment in some African and Asian countries.[80][81] Gender norms in some societies limit women's access to healthcare, contributing to disparities in conditions such as cervical cancer and maternal health outcomes.[82]

Climate change exacerbates the burden of diseases, with rising temperatures facilitating the spread of vector-borne diseases like dengue and malaria.[83] Urban pollution and deforestation contribute to respiratory illnesses and increase the risk of zoonotic diseases.[84][85]

Wealthier nations can allocate resources to advanced healthcare systems and preventive measures, reducing mortality and morbidity rates. In contrast, LMICs often struggle with underfunded health systems and lack of infrastructure.[86][87] The financial burden of out-of-pocket healthcare costs pushes millions into poverty annually, perpetuating cycles of ill health and economic disparity.[88]

To reduce regional and demographic disparities, multi-pronged approaches are essential. These include universal health coverage, context-specific interventions, and policies addressing social determinants of health. Strengthening healthcare systems and prioritizing the needs of vulnerable populations remain critical to achieving equitable health outcomes worldwide.

GLOBAL EFFORTS AND INTERVENTIONS

The fight against the global burden of disease has mobilized governments, international organizations, and stakeholders to implement coordinated initiatives. Through global action plans, international collaborations, and technological innovations, these efforts aim to reduce disease prevalence, enhance healthcare delivery, and promote health equity across diverse populations. Addressing the interconnected challenges of communicable and non-communicable diseases requires sustained commitments, robust funding mechanisms, and adaptive strategies.[1][89]

The Global Action Plan for the Prevention and Control of Noncommunicable Diseases (2013–2030) provides a comprehensive roadmap to reduce premature mortality from NCDs by one-third by 2030. Key strategies include tobacco control, promotion of healthy diets, and improved access to essential medicines.[45][64]

The Global Vaccine Action Plan (GVAP) aims to prevent millions of deaths through equitable access to immunization. This initiative has facilitated significant progress, such as the eradication of wild poliovirus from Africa and increased global vaccine coverage rates.[90][91]

The End TB Strategy envisions a 90% reduction in tuberculosis (TB) deaths and an 80% reduction in incidence by 2030 compared to 2015 levels, emphasizing patient-centered care and strengthened health systems.[92]

Adopted by the United Nations in 2015, the Sustainable Development Goals (SDGs) incorporate health as a core element under Goal 3: “Ensure healthy lives and promote well-being for all at all ages.” Specific targets include ending the epidemics of AIDS, TB, and malaria, combating hepatitis and waterborne diseases, and achieving universal health coverage.[93][94] The SDGs promote a cross-sectoral approach, recognizing the links between health outcomes and education, gender equality, clean water, and sustainable cities.[95]

Role of International Collaborations and Funding

The Global Fund to Fight AIDS, Tuberculosis, and Malaria has disbursed over $50 billion since its inception, saving an estimated 50 million lives by improving access to prevention, treatment, and care.[96]

Gavi, the Vaccine Alliance, has played a pivotal role in improving immunization rates in LMICs, particularly through the introduction of new vaccines against HPV, rotavirus, and pneumococcus.[97][98]

The Access to COVID-19 Tools (ACT) Accelerator exemplifies a global funding model to ensure equitable access to diagnostics, therapeutics, and vaccines during a pandemic. The COVAX initiative under ACT has delivered over 2 billion COVID-19 vaccine doses globally.[99][100]

Health Impact Bonds, such as those used for maternal and child health, enable private investors to support health projects with returns linked to successful outcomes.[101]

Innovations in Disease Tracking, Prevention, and Treatment

Disease Surveillance and Data Analytics: Advances in digital health and artificial intelligence (AI) are transforming disease tracking. Platforms like the Global Health Observatory (GHO) and the HealthMap Project provide real-time data for monitoring outbreaks and assessing health trends.[102][103] Genomic epidemiology, exemplified during the COVID-19 pandemic, facilitated the rapid tracking of viral mutations and informed public health responses.[104]

Prevention Strategies: Vaccination Innovations: mRNA vaccine technology, initially developed for COVID-19, holds promise for other diseases, including influenza, Zika virus, and even cancer.[105][106] Community-Based Interventions: Programs such as integrated vector management for malaria and grassroots health campaigns for maternal care have shown significant success in LMICs.[107][108]

Treatment Advances: Universal Health Coverage (UHC) initiatives, such as those implemented in Thailand and Rwanda, demonstrate the potential for ensuring access to essential healthcare services without financial hardship.[109][110] Precision medicine is revolutionizing cancer care by tailoring treatments based on individual genetic profiles, improving outcomes and reducing side effects.[111]

While global efforts have achieved significant milestones, barriers such as insufficient funding, geopolitical conflicts, and health system inefficiencies persist. Moving forward, the global health community must prioritize sustainable financing, strengthen health systems, and promote equitable access to innovations. Collaborative governance and technological advancements will play a critical role in addressing emerging challenges and achieving universal health goals.

CHALLENGES AND GAPS

Despite substantial progress in addressing global health challenges, significant barriers remain in reducing the global burden of both communicable and non-communicable diseases (NCDs). These challenges are multifaceted and include structural inequalities, emerging threats such as antimicrobial resistance (AMR) and climate change, and gaps in data collection and monitoring. Overcoming these barriers requires not only continued investment in healthcare infrastructure and innovative technologies but also targeted policy interventions and international collaboration.

Healthcare Inequalities:

Healthcare inequalities are a persistent challenge that hinders global efforts to combat the burden of disease. Disparities in access to healthcare are particularly evident between high-income and low- and middle-income countries (LMICs), where the lack of adequate health systems exacerbates both communicable and non-communicable diseases.[112][113]

Access to healthcare: In many LMICs, the healthcare infrastructure is underfunded and lacks sufficient personnel, medical supplies, and technology. This results in poor disease prevention, late diagnosis, and limited access to life-saving treatments.[114]

Health Financing: According to the World Health Organization (WHO), over 100 million people are pushed into poverty each year due to catastrophic health expenditures, with the poorest populations being the most affected.[88][115] This makes it difficult for

countries to invest in comprehensive health services for their populations, particularly in the areas of prevention and chronic disease management.

Antimicrobial Resistance (AMR):

AMR is one of the most pressing health threats of the 21st century, contributing to the increasing difficulty in treating infections and leading to higher mortality rates. The misuse and overuse of antibiotics in humans, animals, and agriculture have accelerated the spread of resistant pathogens.[116][117] The Global Action Plan on AMR developed by the WHO emphasizes the urgent need for international collaboration to reduce the spread of resistant infections through better surveillance, stewardship, and the development of new antibiotics.[118] The economic burden of AMR is also significant, as it complicates treatments for common conditions like pneumonia, tuberculosis, and urinary tract infections, and could potentially lead to longer hospital stays and more intensive care needs.[119][120]

Lifestyle Factors and NCDs:

The rising burden of non-communicable diseases (NCDs) such as cardiovascular diseases, cancers, and diabetes is heavily influenced by urbanization and changing lifestyles. Poor diet, lack of physical activity, tobacco use, and alcohol consumption are key risk factors that contribute to the increasing prevalence of these diseases.[121][122] Urbanization has led to the proliferation of unhealthy food environments and sedentary lifestyles, particularly in rapidly growing cities in LMICs. The marketing of ultra-processed foods and sugary drinks has been linked to rising obesity rates and associated chronic diseases.[123][124] Additionally, aging populations in many high-income countries and increasing life expectancy in LMICs have led to a higher prevalence of age-related diseases, further exacerbating healthcare demands.[125]

Limitations in Data Collection and Monitoring

Data Gaps and Inadequate Surveillance: Reliable and comprehensive health data is essential for tracking disease trends, allocating resources, and informing public health policy. However, many countries, especially in sub-Saharan Africa and South Asia, face significant challenges in collecting timely and accurate data. This results in underreporting of diseases, particularly for communicable diseases such as tuberculosis, malaria, and HIV/AIDS.[126] The Global Burden of Disease (GBD) study, which tracks the burden of diseases across nations, has helped fill some of these gaps. However, inconsistencies in data quality, variations in reporting practices, and lack of infrastructure for disease surveillance in some regions continue to hinder efforts to understand the true scale of the global disease burden.[127] Furthermore, data on non-communicable diseases like diabetes and hypertension remains scarce in many low-resource settings, limiting the ability to design targeted interventions.[128]

Weaknesses in Health Systems and Data Integration: Many countries still lack integrated health information systems that can effectively connect hospital records, epidemiological data, and demographic information to guide health policy. Fragmented data systems make it difficult to identify emerging health trends or assess the effectiveness of interventions on a large scale.[129] Big data analytics and artificial intelligence offer opportunities to enhance disease surveillance and public health response. However, these technologies require substantial investment in infrastructure and capacity-building in LMICs.[130]

Future Threats

The growing threat of climate change has profound implications for global health, especially regarding the spread of infectious diseases. Changes in temperature, precipitation patterns, and extreme weather events affect the spread of vector-borne diseases like malaria, dengue, and Zika virus.[131][132] Additionally, climate-induced displacement, rising sea levels, and water scarcity increase vulnerability to waterborne diseases and exacerbate malnutrition, particularly in marginalized communities.[133] According to the Lancet Countdown on Health and Climate Change, the health impacts of climate change are already being felt and are expected to worsen, putting immense pressure on health systems globally.[83]

Emerging infectious diseases, such as COVID-19, Ebola, and Zika, highlight the vulnerabilities of global health systems in responding to novel threats. The increasing frequency

of zoonotic spillovers—diseases transmitted from animals to humans—poses a continuous risk to public health.[134][135] While surveillance systems for emerging pathogens have improved, the speed of transmission and the lack of preparedness in many countries remain critical challenges. The rise of antimicrobial resistance compounds these challenges by making it more difficult to treat emerging infections.[136] Further, new pathogens may also result in long-term health complications, such as the post-viral syndrome seen in COVID-19 patients, creating an additional burden on healthcare systems and long-term care infrastructure.[137]

While progress has been made in addressing both communicable and non-communicable diseases, significant challenges persist. Inequalities in healthcare access, the rise of antimicrobial resistance, and the limitations in health data collection impede efforts to combat disease burdens effectively. Furthermore, emerging threats, such as climate change and new pathogens, pose serious risks to global health and require urgent, coordinated responses. Addressing these challenges demands continued investment in healthcare systems, data infrastructure, and international collaboration to protect global health in the face of evolving threats.

Conclusion

The global burden of disease continues to be a significant challenge, with both communicable and non-communicable diseases impacting populations worldwide. While communicable diseases, such as HIV/AIDS, tuberculosis, malaria, and emerging diseases like COVID-19, remain major public health concerns, the rise of non-communicable diseases (NCDs) such as cardiovascular diseases, cancers, and diabetes is becoming increasingly prominent. The intersection of these two categories of diseases, along with regional disparities, has exacerbated healthcare burdens, particularly in low-income settings. Addressing this complex global health landscape requires coordinated efforts at the policy, healthcare, and community levels. Strengthening healthcare systems, promoting early diagnosis, improving access to essential medicines, and addressing lifestyle factors are crucial for managing both communicable and non-communicable diseases effectively. Furthermore, integrating efforts to prevent and treat these diseases, while considering the dual burden they impose on health systems, is essential for long-term success. International collaborations and targeted interventions will be critical in reducing health inequities and advancing progress toward achieving sustainable health outcomes globally. A comprehensive approach, focusing on prevention, treatment, and health promotion, is necessary to meet the challenges posed by these diseases and improve population health worldwide.

References

1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222.
2. World Health Organization. Noncommunicable Diseases Fact Sheet. WHO; 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
3. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444-457.
4. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010;58(4):258-266.
5. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590.
6. Nugent R. A chronology of global assistance funding for NCDs: 1990–2019. Glob Health. 2020;16:31.
7. Marmot M, Allen J, Bell R, Bloomer E, Goldblatt P. WHO European review of social determinants of health and the health divide. Lancet. 2012;380(9846):1011-1029.
8. World Health Organization. Communicable diseases. WHO; 2023. Available at: https://www.who.int/
9. UNAIDS. Global HIV & AIDS statistics – Fact sheet. UNAIDS; 2023. Available at: https://www.unaids.org
10. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS by the Numbers 2022. Geneva: UNAIDS; 2022.

11. World Health Organization. Global tuberculosis report 2022. Geneva: WHO; 2022.
12. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: The role of risk factors and social determinants. Soc Sci Med. 2009;68(12):2240-2246.
13. World Health Organization. World malaria report 2022. Geneva: WHO; 2022.
14. White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet. 2014;383(9918):723-735.
15. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/
16. The Lancet COVID-19 Commission. Lessons for the future from the COVID-19 pandemic. Lancet. 2023;401(10385):1-3.
17. Gallup JL, Sachs JD. The economic burden of malaria. Am J Trop Med Hyg. 2001;64(1_suppl):85-96.
18. O'Donnell J, Johnson M, Longo F. COVID-19 and its impact on routine immunization: Challenges and responses. Vaccine. 2023;41(10):1442-1450.
19. Goffman E. Stigma: Notes on the Management of Spoiled Identity. Simon and Schuster; 2009.
20. Greenwood B. The contribution of vaccination to global health: Past, present and future. Phil Trans R Soc B. 2014;369(1645):20130433.
21. Andre FE, Booy R, Bock HL, et al. Vaccination greatly reduces disease, disability, death, and inequity worldwide. Bull World Health Organ. 2008;86(2):140-146.
22. Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015;526(7572):207-211.
23. The Global Fund. Annual report 2022. Geneva: The Global Fund; 2022.
24. World Health Organization. Noncommunicable diseases. WHO; 2023. Available at: https://www.who.int
25. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-1249.
26. Beaglehole R, Bonita R, Horton R, et al. Priority actions for the non-communicable disease crisis. Lancet. 2011;377(9775):1438-1447.
27. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med. 2013;369(14):1336-1343.
28. World Health Organization. Cardiovascular diseases (CVDs) Fact Sheet. WHO; 2023. Available at: https://www.who.int
29. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
30. Prager GW, Braga S, Bystricky B, et al. Global cancer control: Responding to the growing burden, rising costs, and inequalities in access. ESMO Open. 2018;3(2):e000285.
31. International Diabetes Federation. IDF Diabetes Atlas 10th Edition. Brussels, Belgium: IDF; 2021.
32. GBD Chronic Respiratory Disease Collaborators. Global burden of chronic respiratory diseases and their risk factors, 1990–2015. Lancet Respir Med. 2017;5(6):487-507.
33. United Nations. World Urbanization Prospects: The 2018 Revision. New York: UN DESA; 2018.
34. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. Lancet. 2020;395(10226):795-808.
35. Bloom DE, Chatterji S, Kowal P, et al. Macroeconomic implications of population ageing and selected policy responses. Lancet. 2015;385(9968):649-657.
36. Ezzati M, Riboli E. Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med. 2013;369(10):954-964.
37. Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448-457.
38. Chen S, Kuhn M, Prettner K, Bloom DE. Noncommunicable diseases attributable to tobacco use in China: Macroeconomic burden and policy implications. PLoS One. 2021;16(4):e0249271.
39. Bloom DE, Cafiero ET, Jané-Llopis E, et al. The global economic burden of noncommunicable diseases. Geneva: World Economic Forum; 2011.
40. World Bank. The Growing Burden of Non-Communicable Diseases. Washington, DC: World Bank; 2022.
41. Frieden TR. A framework for public health action: The health impact pyramid. Am J Public Health. 2010;100(4):590-595.
42. WHO Global Health Observatory. NCD Risk Factors. Available at: https://www.who.int/data/gho
43. Bauman AE, Petersen CB, Blond K, Rangul V, Hardy LL. The descriptive epidemiology of sedentary behavior. Springer. 2018;9:45-66.

44. Mozaffarian D, Afshin A, Benowitz NL, et al. Population approaches to improve diet, physical activity, and smoking habits: A scientific statement from the American Heart Association. Circulation. 2012;126(12):1514-1563.

45. World Health Organization. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2030. Geneva: WHO; 2013.

46. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(S1):4-13.

47. World Health Organization. Hepatitis B. WHO; 2023. Available at: https://www.who.int

48. Bruni L, Albero G, Serrano B, et al. Human Papillomavirus and Related Diseases Report. Barcelona: ICO/IARC Information Centre on HPV and Cancer; 2021.

49. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2020: A worldwide analysis. Lancet Glob Health. 2020;8(2):e191-e203.

50. Plummer M, de Martel C, Vignat J, et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136(2):487-490.

51. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525-1533.

52. Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: A scientific statement from the American Heart Association. Circulation. 2019;140(2):98-124.

53. Rabkin M, Nishtar S. Scaling up chronic care systems: Leveraging HIV programs to support noncommunicable disease services. J Acquir Immune Defic Syndr. 2011;57(Suppl 2):S87-S90.

54. World Health Organization. Integrated health services for HIV and NCDs. WHO; 2022. Available at: https://www.who.int

55. Su TH, Liu CJ, Tseng TC, et al. Long-term effects of hepatitis B immunoglobulin and nucleoside analogs on prevention of mother-to-child transmission of HBV. Clin Gastroenterol Hepatol. 2020;18(13):2875-2882.

56. Weiss MG, Ramakrishna J. Stigma interventions and research for international health. Lancet. 2006;367(9509):536-538.

57. Triant VA. HIV infection and coronary heart disease: An intersection of epidemics. J Infect Dis. 2012;205(Suppl 3):S355-S361.

58. Sankaranarayanan R, Basu P, Kaur P, et al. Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts. Lancet Oncol. 2019;20(11):e637-e644.

59. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-550.

60. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: A cohort study. Lancet Diabetes Endocrinol. 2023;11(5):356-368.

61. Marmot M, Allen JJ. Social determinants of health equity. Am J Public Health. 2014;104(Suppl 4):S517-S519.

62. World Health Organization. Malaria Fact Sheet. WHO; 2023. Available at: https://www.who.int

63. Snow RW, Sartorius B, Kyalo D, et al. The prevalence of Plasmodium falciparum in sub-Saharan Africa since 1900. Nature. 2017;550(7677):515-518.

64. Beaglehole R, Bonita R, Horton R, et al. Priority actions for the non-communicable disease crisis. Lancet. 2011;377(9775):1438-1447.

65. African Union. Africa's Health Status 2023. Addis Ababa: AU; 2023.

66. WHO Regional Office for Southeast Asia. Health situation in the South-East Asia Region 2022. New Delhi: WHO SEARO; 2022.

67. Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India: Current epidemiology and future directions. Circulation. 2016;133(16):1605-1620.

68. OECD. Health at a Glance 2023. Paris: OECD; 2023.

69. UNICEF. Levels & Trends in Child Mortality 2022. New York: UNICEF; 2022.

70. Black RE, Victora CG, Walker SP, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet. 2013;382(9890):427-451.

71. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults 1980–2013: A systematic analysis. Lancet. 2014;384(9945):766-781.

72. Lobstein T, Jackson-Leach R, Moodie ML, et al. Child and adolescent obesity: Part of a bigger picture. Lancet. 2015;385(9986):2510-2520.

73. WHO. Global strategy and action plan on ageing and health 2020. Geneva: WHO; 2020.

74. Beard JR, Officer A, de Carvalho IA, et al. The World report on ageing and health: A policy framework for healthy ageing. Lancet. 2016;387(10033):2145-2154.

75. Centers for Disease Control and Prevention (CDC). Flu and Older Adults. CDC; 2023. Available at: https://www.cdc.gov

76. John Hopkins Medicine. COVID-19 and Older Adults. Available at: https://www.hopkinsmedicine.org

77. WHO. Air pollution and child health: Prescribing clean air. Geneva: WHO; 2018.

78. Gracey M, King M. Indigenous health part 1: Determinants and disease patterns. Lancet. 2009;374(9683):65-75.

79. Anderson I, Robson B, Connolly M, et al. Indigenous and tribal peoples' health (The Lancet–Lowitja Institute Global Collaboration): A population study. Lancet. 2016;388(10040):131-157.

80. UNAIDS. Addressing HIV stigma and discrimination in healthcare settings. UNAIDS; 2022.

81. Parker R, Aggleton P. HIV and AIDS-related stigma and discrimination: A conceptual framework and implications for action. Soc Sci Med. 2003;57(1):13-24.

82. Sen G, Östlin P. Gender inequity in health: Why it exists and how we can change it. Glob Public Health. 2008;3(Suppl 1):1-12.

83. Watts N, Amann M, Arnell N, et al. The 2020 report of The Lancet Countdown on health and climate change: Responding to converging crises. Lancet. 2021;397(10269):129-170.

84. Haines A, Ebi K. The imperative for climate action to protect health. N Engl J Med. 2019;380(3):263-273.

85. Patz JA, Frumkin H, Holloway T, Vimont DJ, Haines A. Climate change: Challenges and opportunities for global health. JAMA. 2014;312(15):1565-1580.

86. World Bank. Universal health coverage: Addressing challenges in LMICs. Washington DC: World Bank; 2022.

87. WHO. Global spending on health 2023. Geneva: WHO; 2023.

88. Xu K, Evans DB, Carrin G, Aguilar-Rivera AM, Musgrove P, Evans T. Protecting households from catastrophic health expenditures. Health Aff. 2007;26(4):972-983.

89. Horton R. Offline: Planetary health is about more than disease. Lancet. 2021;398(10308):881.

90. Global Vaccine Action Plan Secretariat. Decade of Vaccines Report. Geneva: WHO; 2020.

91. Polio Eradication Initiative. Progress towards polio eradication 2023. Available at: https://polioeradication.org

92. WHO. The End TB Strategy. Geneva: WHO; 2015. Available at: https://www.who.int

93. United Nations. Sustainable Development Goals 2015. Available at: https://sdgs.un.org

94. Sachs JD, Schmidt-Traub G, Kroll C, Lafortune G, Fuller G. Sustainable Development Report 2023. Cambridge: Cambridge University Press; 2023.

95. Prüss-Ustün A, Wolf J, Corvalán C, et al. Preventing disease through healthy environments: A global assessment of the burden of disease from environmental risks. Geneva: WHO; 2016.

96. The Global Fund. Results report 2023. Geneva: The Global Fund; 2023.

97. Gavi, the Vaccine Alliance. Annual Progress Report 2023. Available at: https://www.gavi.org

98. Jit M, Hutubessy R, Png ME, et al. The broader economic impact of vaccination: Reviewing and appraising the strength of evidence. BMC Med. 2015;13(1):209.

99. WHO. ACT-Accelerator Strategic Review 2022. Geneva: WHO; 2022.

100. Berkley S. COVAX explained: Making COVID-19 vaccines accessible to the world. Gavi; 2022. Available at: https://www.gavi.org

101. Rangan M, Schanz M, Rishty M. Using health impact bonds to achieve SDGs. World Econ Forum White Paper. 2021.

102. WHO. Global Health Observatory. Available at: https://www.who.int

103. Freifeld CC, Mandl KD, Reis BY, Brownstein JS. HealthMap: Global infectious disease monitoring through online media. N Engl J Med. 2008;358(21):2156-2158.

104. Hadfield J, Megill C, Bell SM, et al. Nextstrain: Real-time tracking of pathogen evolution. Bioinformatics. 2018;34(23):4121-4123.

105. Jackson NA, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: A biotechnology breakthrough. Nat Rev Drug Discov. 2020;19(12):845-862.

106. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines: Emerging technology for infectious diseases and beyond. Nat Rev Drug Discov. 2018;17(4):261-279.

107. WHO. Integrated Vector Management Strategy. Geneva: WHO; 2015.

108. Lawn JE, Kerber K, Enweronu-Laryea C, Massee Bateman O. Newborn survival in low-resource settings—are we delivering? BJOG. 2009;116(1):49-59.

109. Tangcharoensathien V, Mills A, Palu T. Accelerating health equity: The key role of universal health coverage in the Sustainable Development Goals. BMC Med. 2015;13:101.

110. Binagwaho A, Scott KW. Improving the world's health through the post-2015 development agenda: Perspectives from Rwanda. Int J Health Policy Manag. 2015;4(4):203-205.

111. Jain KK. Personalized medicine for cancer: From drug development into clinical practice. Expert Opin Pharmacother. 2017;18(18):1701-170

112. Chatterjee S, Suryawanshi S, Patel S, et al. Healthcare access and inequality in low-resource settings: A global perspective. Lancet Global Health. 2020;8(7):e931-e940.

113. WHO. Universal health coverage: The path to achieving the SDGs. Geneva: WHO; 2017.

114. Horton R. Offline: Global health inequity. Lancet. 2020;396(10249):1491.

115. OECD. The looming challenge of non-communicable diseases: A reality check. OECD Health Working Papers. 2022.

116. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: A worldwide challenge. Lancet. 2016;387(10014):1723-1732.

117. WHO. Global Action Plan on Antimicrobial Resistance. Geneva: WHO; 2015.

118. WHO. Antimicrobial Resistance: Global Report on Surveillance. Geneva: WHO; 2014.

119. O'Neill J. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance. 2014.

120. Ventola CL. The antibiotic resistance crisis: Part 1: Causes and threats. Pharm Ther. 2015;40(4):277-283.

121. WHO. Global Status Report on Noncommunicable Diseases 2014. Geneva: WHO; 2014.

122. Popkin BM, Reardon T, Henson S. The global nutrition transition: The pandemic of obesity in developing countries. Nut Rev. 2020;71(1):1-24.

123. Hawkes C, Ruel M, Salm L, et al. Global food systems and health: Building a more sustainable food future. Lancet. 2018;392(10158):331-350.

124. Prentice AM, Jebb SA. Obesity in developing countries: A growing concern. Int J Obes. 2004;28(3):113-116.

125. World Population Ageing 2020. United Nations Department of Economic and Social Affairs. Population Division, 2020.

126. World Health Organization. Tuberculosis country profiles. Geneva: WHO; 2021. Available at: https://www.who.int

127. Murray CJ, Aravkin AY, Zheng P, et al. Global burden of disease study 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222.

128. Narayan KMV, Boyle JP, Thompson TJ, et al. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007;30(6):1562-1566.

129. Dash S, Chatterjee S. Integrated health information systems and the future of disease surveillance. J Health Inf Manage. 2018;22(2):63-72.

130. Caraballo L, Martinelli L, Finkelstein A, et al. Big data in healthcare: Opportunities and challenges. J Med Syst. 2020;44(1):21-29.

131. Patz JA, Campbell-Lendrum D, Holloway T, et al. Impact of regional climate change on human health. Nature. 2005;438(7066):310-317.

132. WHO. Malaria and Climate Change: The Role of Weather and Climate. Geneva: WHO; 2020.

133. Haines A, Kovats RS, Campbell-Lendrum D, et al. Climate change and human health: Impacts, vulnerability, and public health. Public Health. 2006;120(7):585-596.

134. Gisselquist D. Emerging infectious diseases: Global health and the threats from zoonoses. J Global Health. 2014;4(2):210-222.

135. Fisher-Hoch SP, Vinetz JM. Emerging zoonotic diseases. Am J Public Health. 2014;104(8):1455-1461.

136. Lewis KD, Butler WR. Antimicrobial resistance and emerging infectious diseases: A call for greater global health surveillance. Epidemiol Infect. 2020;148:1-3.

137. WHO. Post-COVID-19 Syndrome. Geneva: WHO; 2022.